Enlivex Therapeutics Ltd
NASDAQ:ENLV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Enlivex Therapeutics Ltd
Cash from Operating Activities
Enlivex Therapeutics Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Cash from Operating Activities
-$10.4m
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash from Operating Activities
$25.5m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash from Operating Activities
-$162.4m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash from Operating Activities
-$7.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Cash from Operating Activities
-$20.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-1%
|
|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Cash from Operating Activities
-₪11.8m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Enlivex Therapeutics Ltd
Glance View
Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
See Also
What is Enlivex Therapeutics Ltd's Cash from Operating Activities?
Cash from Operating Activities
-10.4m
USD
Based on the financial report for Dec 31, 2025, Enlivex Therapeutics Ltd's Cash from Operating Activities amounts to -10.4m USD.
What is Enlivex Therapeutics Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
2%
Over the last year, the Cash from Operating Activities growth was 20%. The average annual Cash from Operating Activities growth rates for Enlivex Therapeutics Ltd have been 24% over the past three years , 1% over the past five years , and 2% over the past ten years .
